title: Interleukin-7 enhances colony growth and induces CD20 antigen of a Ph+ acute lymphoblastic leukemia cell line, OM9;22.
abstract: A newly established human leukemia cell line, OM9;22, is reported, with B-precursor immunophenotype (CD10+ CD19+ CD22+ HLA- DR+ C mu-) and CD13 antigen, originated from a 19-year-old female patient with Philadelphia (Ph) chromosome-positive acute lymphoblastic leukemia (ALL). The OM9;22 cells carry a Philadelphia (Ph) translocation and hybrid message detected by a minor-breakpoint cluster region (BCR) exon 1/ABL exon 2 junctional probe using reverse transcriptase polymerase chain reaction. The genetic alterations are consistent with those observed in the donor's leukemia cells, allowing us to conclude that this cell line is a minor-BCR rearranged Ph-positive ALL (Ph+ ALL). Colony formation of the OM9;22 cells in methylcellulose culture is enhanced by the addition of human interleukin 7 (IL-7). In liquid culture, more than 80% of IL-7-treated OM9;22 cells express CD20 antigen but fail to express surface immunoglobulins or cytoplasmic mu-chain, indicating that the cells have a potential of limited maturation by IL-7. By contrast, IL-4 suppresses the colony formation of the OM9;22 cells. These findings suggest that this cell line might be a model of B-precursor human leukemia with proliferative capability by IL-7.
authors.affiliation: First Department of Internal Medicine, Tokyo Medical College, Japan.
authors.forename: K
authors.initials: K
authors.lastname: Ohyashiki
authors.forename: J
authors.initials: J
authors.lastname: Miyauchi
authors.forename: J H
authors.initials: JH
authors.lastname: Ohyashiki
authors.forename: M
authors.initials: M
authors.lastname: Saito
authors.forename: M
authors.initials: M
authors.lastname: Yaguchi
authors.forename: Y
authors.initials: Y
authors.lastname: Inatomi
authors.forename: S
authors.initials: S
authors.lastname: Nakazawa
authors.forename: H
authors.initials: H
authors.lastname: Waca
authors.forename: S
authors.initials: S
authors.lastname: Mizutani
authors.forename: Y
authors.initials: Y
authors.lastname: Matsuo
mesh_terms: D000328:Adult; D015703:Antigens, CD / Q000378:metabolism*; D018951:Antigens, CD20; D000944:Antigens, Differentiation, B-Lymphocyte / Q000378:metabolism*; D001483:Base Sequence; D005260:Female; D015326:Gene Rearrangement, B-Lymphocyte, Heavy Chain; D006801:Humans; D007143:Immunoglobulin Heavy Chains / Q000235:genetics; D016130:Immunophenotyping; D066298:In Vitro Techniques; D015851:Interleukin-7 / Q000494:pharmacology*; D007621:Karyotyping; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000276:immunology / Q000473:pathology*; D008969:Molecular Sequence Data; D009838:Oligodeoxyribonucleotides / Q000737:chemistry; D015452:Precursor B-Cell Lymphoblastic Leukemia-Lymphoma / Q000276:immunology / Q000473:pathology*; D011971:Receptors, Immunologic / Q000378:metabolism; D020395:Receptors, Interleukin-7; D014407:Tumor Cells, Cultured
chemical_list: D015703:Antigens, CD; D018951:Antigens, CD20; D000944:Antigens, Differentiation, B-Lymphocyte; D007143:Immunoglobulin Heavy Chains; D015851:Interleukin-7; D009838:Oligodeoxyribonucleotides; D011971:Receptors, Immunologic; D020395:Receptors, Interleukin-7